200
Participants
Start Date
April 30, 2013
Primary Completion Date
May 31, 2017
Study Completion Date
July 31, 2017
Rispéridone, aripiprazole, olanzapine
"Study:~We propose a prospective, interventional multicenter study.~Method:~Both in and out patients may be included in the study Patients will be recruited over a period of 24 months. They will be followed up for 12 months. Each patient will receive one year of therapeutic monitoring after the introduction of the antipsychotic drug.~The therapeutic monitoring will include clinical, electrocardiographical, and laboratory assessments. These assessments are performed at baseline (before prescribing treatment) and at 1 month (M1), at 3 months (M3), 6 months (M6), 9 months (M9), and at 12 months (M12) after the first prescription of the antipsychotic drug."
CH St Jean de Dieu, Lyon
Ch le Vinatier, Bron
CH Henri laborit, Poitiers
CH de Cannes, Cannes
CH D'antibes, Antibes
Fondation Vallée, Gentilly
CHRU de Lille, Lille
Centre Hospitalier Spécialisé Esquirol, Limoges
HCL, Lyon
CHU de Nancy, Nancy
CHU de Nantes, Nantes
AP-HP, Paris
CHU de Toulouse, Toulouse
Service de psychiatrie de l'enfant et de l'adolescent, Nice
Centre Hospitalier Universitaire de Nice
OTHER